SEARCH

SEARCH BY CITATION

References

  • 1
    Pirson Y, Alexandre GPJ, van Ypersele de Strihou C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296:194196.MEDLINE
  • 2
    Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG, Dauphinee WD, Hollomby DJ, Guttmann RD. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984; 37:461466.MEDLINE
  • 3
    Degos F, Lugassy C, Degott C, Debure A, Carnot F, Thiers V, Tiollais P, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94:151156.MEDLINE
  • 4
    Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29:257263.MEDLINE
  • 5
    Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ, Kuo PC, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64:17811786.MEDLINE
  • 6
    Fong T-L, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002; 73:8589.MEDLINE
  • 7
    Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, et al. The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers. Transplantation 1994; 57:490497.MEDLINE
  • 8
    Rodrigues A, Morgado T, Areias J, Silvestre F, Pinho L, Alves H, Castro-Henriques A, et al. Limited benefits of IFN-α therapy in renal graft candidates with chronic viral hepatitis B or C. Transplant Proc 1997; 29:777780.MEDLINE
  • 9
    Monteon FJ, Contreras AM, Espinoza L, Vazquez G, Aguilar S, Cueva L. Interferon alfa-2b in renal transplant recipients with viral chronic hepatitis: a pilot study. Transplant Proc 1996; 28:33063308.MEDLINE
  • 10
    Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1:989990.MEDLINE
  • 11
    Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993; 42(RR-4):118.
  • 12
    Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001; 15:813832.MEDLINE
  • 13
    Park S-K, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, Han DJ, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16:22222228.MEDLINE
  • 14
    Mosconi G, Scolari MP, Manna C, Canova C, Cristino S, Campieri C, D'Arcangelo L, et al. Lamivudine in recurrent hepatitis B after renal transplantation. Transplant Proc 2001; 33:18731874.MEDLINE
  • 15
    Lee W-C, Wu M-J, Cheng C-H, Chen C-H, Shu K-H, Lian J-D. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38:10741081.MEDLINE
  • 16
    Lewandowska D, Durlik M, Kukula K, Cieciura T, Ciecierski R, Walewska-Zielecka B, Szmidt J, et al. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc 2000; 32:13691370.MEDLINE
  • 17
    Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. Transplant Proc 2000; 32:384385.MEDLINE
  • 18
    Mouquet C, Bernard B, Poynard T, Thibault V, Opolon P, Coriat P, Bitker MO. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant Proc 2000; 32:2762.MEDLINE
  • 19
    Tsai M-K, Lai M-Y, Hu R-H, Lee C-J, Lee P-H. Managing hepatitis B reactivation in renal transplant recipients: a 12-year review with emphasis on early detection and early use of lamivudine. Transplant Proc 2000; 32:19351936.MEDLINE
  • 20
    Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P, Kovarik J. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70:14041407.MEDLINE
  • 21
    Goffin E, Horsmans Y, Cornu C, Squifflet J-P, Pirson Y. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998; 66:407409.MEDLINE
  • 22
    Jung YO, Lee YS, Yang WS, Han DJ, Park JS, Park S-K. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66:733737.MEDLINE
  • 23
    Rostaing L, Henry S, Cisterne J-M, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64:16241627.MEDLINE
  • 24
    Pol S, Saltiel C, Legendre C, Carnot F, Driss F, Berthelot P, Brechot C, et al. Efficacy of adenine arabinoside 5'-monophosphate in kidney recipients with chronic active hepatitis B: a pilot study. Transplant Proc 1993; 25:14461449.MEDLINE
  • 25
    Garnier J-L, Chossegros P, Daoud S, Chevallier P, Dubernard J-M, Trepo C, Touraine J-L. Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients. Transplant Proc 1997; 29:817.MEDLINE
  • 26
    Tang S, Ho SKN, Moniri K, Lai KN, Chan TM. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 73:148151.MEDLINE
  • 27
    Faraidy KA, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64:926928.MEDLINE
  • 28
    Chan T-M, Wu P-C, Li F-K, Lai C-L, Cheng IKP, Lai K-N. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177181.MEDLINE
  • 29
    Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Pre-emptive lamivudine therapy based on HBV DNA in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36:12461252.
  • 30
    Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:10091022.MEDLINE
  • 31
    Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69:20902094.MEDLINE
  • 32
    Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, Lamy P, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68:19121914.MEDLINE
  • 33
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107113.MEDLINE
  • 34
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134.MEDLINE
  • 35
    Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Rutkiewicz V, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy [Abstract]. Hepatology 2001; 34(Part 2):340A.
  • 36
    Dunkle LM. ACH-126, 443: a second generation anti-HBV and anti-HIV L-nucleoside analogue [Abstract]. Antiviral Res 2001; 52(Suppl):47.
  • 37
    Perrillo R., Schiff E, Hann H-WL, Buti M, Strasser S, Watkins KM, Moorat AE, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine—Preliminary 24 week results [Abstract]. Hepatology 2001; 34(Part 2):349A.